KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Cme (CME) EBIT (2016 - 2025)

Historic EBIT for Cme (CME) over the last 17 years, with Q3 2025 value amounting to $972.6 million.

  • Cme's EBIT fell 503.81% to $972.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 billion, marking a year-over-year increase of 804.14%. This contributed to the annual value of $3.9 billion for FY2024, which is 1443.08% up from last year.
  • Cme's EBIT amounted to $972.6 million in Q3 2025, which was down 503.81% from $1.1 billion recorded in Q2 2025.
  • Cme's EBIT's 5-year high stood at $1.1 billion during Q2 2025, with a 5-year trough of $613.7 million in Q3 2021.
  • Its 5-year average for EBIT is $854.6 million, with a median of $859.1 million in 2022.
  • Its EBIT has fluctuated over the past 5 years, first plummeted by 2446.09% in 2021, then surged by 2916.35% in 2023.
  • Over the past 5 years, Cme's EBIT (Quarter) stood at $631.7 million in 2021, then grew by 5.79% to $668.3 million in 2022, then rose by 29.16% to $863.2 million in 2023, then rose by 9.72% to $947.1 million in 2024, then increased by 2.69% to $972.6 million in 2025.
  • Its EBIT was $972.6 million in Q3 2025, compared to $1.1 billion in Q2 2025 and $1.1 billion in Q1 2025.